ARWR Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

78.780

Open

78.770

VWAP

77.73

Vol

1.44M

Mkt Cap

10.97B

Low

76.500

Amount

112.08M

EV/EBITDA(TTM)

--

Total Shares

140.86M

EV

10.60B

EV/OCF(TTM)

--

P/S(TTM)

17.79

Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. Its Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, neuromuscular and others. It has over 18 discovered drug candidates in clinical trials ranging from early stage (Phase I) to late stage (Phase III). The Company's pipeline products include plozasiran, zodasiran, olpasiran, ARO-RAGE, SRP-1002, GSK4532990, fazirsiran, daplusiran/tomligisiran, ARO-CFB, ARO-INHBE, ARO-C3, ARO-PNPLA3, SRP-1001 (ARO-DUX4), SRP-1003 (ARO-DM1), SRP-1004 (ARO-ATXN2), and others.

Show More

Events Timeline

(ET)

2026-05-27

07:10:00

Arrowhead Pharmaceuticals Presents Interim Results of ARO-INHBE Clinical Trial

2026-05-26 (ET)

2026-05-26

10:20:00

Arrowhead Pharmaceuticals Presents Clinical Data for Plozasiran

2026-05-07 (ET)

2026-05-07

16:40:00

Arrowhead Pharmaceuticals Q2 Revenue $73.7M Beats Expectations

2026-05-05 (ET)

2026-05-05

08:10:00

Arrowhead Signs Exclusive License Agreement with Madrigal for ARO-PNPLA3

2026-05-01 (ET)

2026-05-01

07:40:00

Arrowhead Pharmaceuticals Receives Approval for Redemplo to Treat FCS

2026-04-24 (ET)

2026-04-24

06:50:00

Arrowhead Pharmaceuticals' REDEMPLO Receives Positive Opinion from EMA

News

Newsfilter

05-26Newsfilter

Arrowhead Pharmaceuticals Presents New Clinical Data for Plozasiran at EAS Congress

PRnewswire

05-12PRnewswire

Cardiovascular Disease Costs Set to Skyrocket, Urgent Need for AI Solutions

Newsfilter

05-12Newsfilter

Cardiovascular Disease Costs Surge, AI Technology Becomes Key

seekingalpha

05-08seekingalpha

Arrowhead Pharmaceuticals Q2 2026 Earnings Call Highlights

Newsfilter

05-04Newsfilter

Arrowhead Pharmaceuticals to Participate in Multiple Upcoming Conferences

CNBC

Latest Wall Street Rating Updates

11 Analyst Rating

Wall Street analysts forecast ARWR stock price to rise

8 Buy

3 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

35.00

Averages

82.00

High

110.00

Current: 0.000

Low

35.00

Averages

82.00

High

110.00

Bernstein

Market Perform

maintain

$35 -> $46

AI Analysis

2026-05-13

Reason

Bernstein

Price Target

$35 -> $46

AI Analysis

2026-05-13

maintain

Market Perform

Reason

Bernstein raised the firm's price target on Arrowhead to $46 from $35 and keeps a Market Perform rating on the shares. Biotech has had a strong start to 2026, up 11% year-to-date, outperforming Pharma and the S&P. The firm's coverage is up 7% year-to-date on a simple-average basis, and down 3% cap weighted - smaller names have outperformed. Overall, Bernstein maintains a positive view on the sector, as it expects M&A and IPO activity to remain healthy, and it views recent changes to FDA leadership as a tailwind, particularly for less mature companies.

Chardan

Buy

maintain

$80 -> $90

2026-05-08

Reason

Chardan

Price Target

$80 -> $90

2026-05-08

maintain

Buy

Reason

Chardan raised the firm's price target on Arrowhead to $90 from $80 and keeps a Buy rating on the shares post the fiscal Q2 report. The U.S. launch of Redemplo is off to a good start, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ARWR

Unlock Now

Valuation Metrics

The current forward P/E ratio for Arrowhead Pharmaceuticals Inc (ARWR.O) is 111.11, compared to its 5-year average forward P/E of -7.62. For a more detailed relative valuation and DCF analysis to assess Arrowhead Pharmaceuticals Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-7.62

Current PE

111.11

Overvalued PE

31.33

Undervalued PE

-46.57

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-13.51

Current EV/EBITDA

-19.87

Overvalued EV/EBITDA

22.89

Undervalued EV/EBITDA

-49.92

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

5Y Average PS

22.83

Current PS

33.04

Overvalued PS

34.98

Undervalued PS

10.68

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

what is a good stock to buy into right now

Intellectia · 142 candidates

Market Cap: >= 1000.00MRegion: USPrice: >= $10.00Quarter Revenue Yoy Growth: >= 3.0%Analyst Consensus: Moderate Buy, Strong BuyRsi Category: moderateBeta: LowRisk, ModerateRisk, HighRisk, NegativeBetaMoving Average Relationship: PriceAboveMA20

Ticker

Name

Market Cap$

Arrowhead Pharmaceuticals Inc

10.49B

BROOKFIELD ASSET MANAGEMENT LTD

79.34B

Vir Biotechnology Inc

1.61B

Madrigal Pharmaceuticals Inc

11.58B

Sprott Inc

3.27B

Turning Point Brands Inc

1.57B

which stock is best before open q2 revenue

Intellectia · 1054 candidates

Revenue Ttm: >= 0

Ticker

Name

Market Cap$

Joby Aviation Inc

8.53B

Arrowhead Pharmaceuticals Inc

10.49B

Precision BioSciences Inc

192.23M

Red Cat Holdings Inc

1.27B

Horizon Technology Finance Corp

288.74M

BridgeBio Pharma Inc

13.47B

us stock are fine.

Intellectia · 791 candidates

Region: USPrice: >= $-100.00Rsi Category: moderateMoving Average Relationship: PriceAboveMA20Week Price Change Pct: >= $-3.00Ema 20: >= -100One Week Rise Prob: >= 55

Ticker

Name

Market Cap$

Neuronetics Inc

98.80M

Maximus Inc

3.77B

FutureFuel Corp

184.67M

SOPHiA GENETICS SA

378.41M

Artesian Resources Corp

334.83M

Sweetgreen Inc

816.13M

good short term investments to go up

Intellectia · 24 candidates

Market Cap: >= 5.00BMoving Average Relationship: PriceAboveMA20Month Price Change Pct: $5.00 - $25.00Option Sentiments: BullishOne Week Rise Prob: >= 70One Week Predict Return: >= 0.0%

Ticker

Name

Market Cap$

Bgc Group Inc

5.60B

CG Oncology Inc

6.20B

Ultrapar Participacoes SA

6.34B

Arrowhead Pharmaceuticals Inc

9.73B

Enel Chile SA

6.31B

Pan American Silver Corp

24.92B

What stocks have a new buy signal today?

Intellectia · 55 candidates

Market Cap: >= 5.00BRegion: USMarket Cap Category: large, mega, midPrice Change Pct: >= $4.00List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceCrossAboveMA20, PriceAboveMA200

Ticker

Name

Market Cap$

Arm Holdings PLC

143.33B

Summit Therapeutics Inc

12.05B

Chewy Inc

9.73B

Planet Labs PBC

11.02B

AST SpaceMobile Inc

33.23B

Rocket Lab Corp

37.62B

give me day trades to buy today

Intellectia · 28 candidates

Price: $5.00 - $100.00Price Change Pct: >= $3.00Support Resistance Relationship: PriceBreakResistanceMonthly Average Dollar Volume: >= 1,000,000

Ticker

Name

Market Cap$

Battalion Oil Corp

194.19M

Venture Global Inc

27.96B

Red Cat Holdings Inc

1.63B

Pinterest Inc

11.63B

AST SpaceMobile Inc

32.49B

Vermilion Energy Inc

1.74B

Intellectia · 2866 candidates

Pe Ttm: <= 10

Ticker

Name

Market Cap$

SL Green Realty Corp

3.35B

Avadel Pharmaceuticals PLC

2.11B

HubSpot Inc

15.84B

Arrowhead Pharmaceuticals Inc

9.42B

PDF Solutions Inc

1.42B

Trivago NV

197.86M

Top Biotechnology/Health Tech

Intellectia · 82 candidates

Weekly Average Turnover: >= 1,000,000Year Price Change Pct: >= $10.00Annual Eps Yoy Growth: >= 10.0%Annual Revenue Yoy Growth: >= 10.0%

Ticker

Name

Market Cap$

Eli Lilly and Co

1.02T

AstraZeneca PLC

280.73B

Novartis AG

278.44B

McKesson Corp

101.61B

argenx SE

50.52B

Alnylam Pharmaceuticals Inc

48.28B

Whales Holding ARWR

Summit Partners Public Asset Management, LLC

Slate Path Capital LP

Fred Alger Management, LLC

Avoro Capital Advisors LLC

Driehaus Capital Management LLC

Artal Group S.A.

Trading Trends

People Also Watch

Frequently Asked Questions

What is Arrowhead Pharmaceuticals Inc (ARWR) stock price today?

The current price of ARWR is 77.91 USD — it has decreased -1.44

What is Arrowhead Pharmaceuticals Inc (ARWR)'s business?

Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. Its Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, neuromuscular and others. It has over 18 discovered drug candidates in clinical trials ranging from early stage (Phase I) to late stage (Phase III). The Company's pipeline products include plozasiran, zodasiran, olpasiran, ARO-RAGE, SRP-1002, GSK4532990, fazirsiran, daplusiran/tomligisiran, ARO-CFB, ARO-INHBE, ARO-C3, ARO-PNPLA3, SRP-1001 (ARO-DUX4), SRP-1003 (ARO-DM1), SRP-1004 (ARO-ATXN2), and others.

What is the price predicton of ARWR Stock?

Wall Street analysts forecast ARWR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARWR is82.00 USD with a low forecast of 35.00 USD and a high forecast of 110.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Arrowhead Pharmaceuticals Inc (ARWR)'s revenue for the last quarter?

Arrowhead Pharmaceuticals Inc revenue for the last quarter amounts to 73.74M USD, decreased -86.41

What is Arrowhead Pharmaceuticals Inc (ARWR)'s earnings per share (EPS) for the last quarter?

Arrowhead Pharmaceuticals Inc. EPS for the last quarter amounts to -0.93 USD, decreased -133.82

How many employees does Arrowhead Pharmaceuticals Inc (ARWR). have?

Arrowhead Pharmaceuticals Inc (ARWR) has 711 emplpoyees as of May 30 2026.

What is Arrowhead Pharmaceuticals Inc (ARWR) market cap?

Today ARWR has the market capitalization of 10.97B USD.